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 Abstract: 
Introduction: Cognitive impairment (CI) is very common in haemodialysis patients and 
associated with reduced functional capacity and mortality. We assessed change in cognitive 
function during haemodialysis and associated risk factors. 
Methods: All patients ≥50 years, on haemodialysis for ≥3 months, no dementia from 2 
dialysis centres were selected. Cognition was assessed before and after a haemodialysis 
session using parallel versions of Montreal Cognitive Assessment (MOCA) tool. Multiple 
regression was used to examine potential confounders. 
Results: 82 patients completed both tests - median age 73 (52–91) years, 59% male, dialysis 
vintage 41 (3– 88) months. 62 (76%) had CI at baseline. Cognition declined over dialysis 
(MOCA 21±4.8 to 19.1±4.1, p<0.001), domains affected were attention, language, 
abstraction and delayed recall. Age and dialysis vintage were independently associated with 
decline. 
Conclusion: Cognitive function declines over a haemodialysis session that has significant 
clinical implications for health literacy, self-management and tasks like driving.  More 
research is needed to find the cause of this. 
Introduction:  
Increasing severity of chronic kidney disease is associated with a graded increase in 
prevalence of cognitive impairment [1,2] and decrease in brain perfusion independent of 
vascular risk factors [3]. Cognitive impairment was three times more common in 
haemodialysis patients than age-matched general population with as many as 70% of 
haemodialysis patients over the age of 55 years suffering from moderate to severe cognitive 
impairment [4,5,6]. A recent meta-analysis showed patients treated with haemodialysis have 
more cognitive impairment than general population with orientation, attention, memory and 
executive function being more affected [7]. Cognitive function dropped significantly after the 
start of haemodialysis and progressed in a stepwise fashion. Cognitive impairment in 
haemodialysis patients was independently associated with higher rates of depression, 
functional impairment and mortality [4,8].  
 
Clustering of atherosclerotic risk factors [8], cannot entirely account for the excess risk of 
cognitive impairment in haemodialysis [9]. There are multiple chronic kidney disease and 
haemodialysis-specific risk factors including oxidative stress, malnutrition and inflammation 
which may be contributory [10]. Incomplete removal of uraemic toxins by haemodialysis 
allowed accumulation of neurotoxins [11] that reduced brain perfusion and blood-brain 
barrier integrity [12]. Moreover, haemodialysis involves repetitive cycles of removing 
varying volumes of fluid, electrolytes and toxins that accumulate between treatments, which 
can lead to complications. For instance, hypotension partially results from fluid removal rates 
exceeding plasma refill rates. Ubiquitous left ventricular hypertrophy and aortic stiffness 
further lower the threshold for haemodialysis to inflict recurrent multi-organ ischemia-
reperfusion injury [13, 14]. Haemodialysis might cause worsening of cognitive impairment 
by inducing haemodynamic instability, fluid shifts, cerebral ischaemia or cerebral oedema 
[10,13,15]. These dynamic changes in blood pressure and perfusion might be associated with 
altered cognition but the data are sparse and conflicting, possibly reflecting differences in 
study design. Several small studies showed cognitive function was best immediately before 
haemodialysis, worse during haemodialysis and improved the day after with a possible link to 
sudden fluid removal or other factor related to the haemodialysis process [4,16-20]. 
 
The aim of this study was to assess systematically the change in cognitive function over a 
single haemodialysis session using the commercially available Montreal Cognitive 
Assessment (MOCA) battery [21], and the relationship between this and a number of putative 
risk factors for cognitive impairment in haemodialysis patients.  
 
Materials and Methods: 
Participants and setting:  
All patients over the age of 50 years from two satellite haemodialysis centres affiliated to the 
main renal centre were selected. Patients in satellite centres were chosen because these 
patients are clinically more stable; satellite dialysis centres are quieter, more spacious with 
adequate lighting and patients dialyse either in side rooms or in open bays where screens are 
available to isolate patients for privacy. Inclusion criteria were: being on maintenance 
haemodialysis for at least 3 months, ability to read and write English, and ability to provide 
informed consent. Exclusion criterion was a known diagnosis of dementia mentioned in the 
medical notes. The age cut off 50 years was chosen for cognitive impairment is reportedly 
more common in haemodialysis patients over this age [5]. 
 
Assessment of cognition and physiological parameters: 
This was a prospective observational study carried out in March 2014. Cognition was 
assessed using the Montreal Cognitive Assessment (MOCA) tool carried out by four research 
assistants who were trained in administering MOCA prior to the study. One researcher (GT) 
who has vast experience in the use of MOCA in old age psychiatry oversaw four research 
assistants who carried out the assessments to ensure correct assessment technique and 
standardization.   
MOCA is a validated screening tool for early cognitive impairment in the general population 
[21]. It has also been validated to screen for cognitive impairment against a battery of 
neuropsychological tests in haemodialysis patients [22[. It assesses eight cognitive domains, 
generating a score of between 0 and 30 - Visuospatial/ Executive 5, Naming 3, Memory 0, 
Attention 6, Language 3, Abstraction 2, Delayed recall 5, Orientation 6. The cut off for 
normal cognition is 26 for the general population [21] and 24 for haemodialysis patients with 
a score <17 considered as severe cognitive impairment [22] . Three parallel English versions 
were used for reassessment to avoid any learning effect. The visuospatial domain of MOCA 
was marked by an independent person who was not part of the research team.  
For each assessment the patient was allowed up to 30 minutes. The first assessment (MOCA 
1) was done either before the start of dialysis session or within the 1st half hour of treatment. 
The second assessment was done in the last half hour of a dialysis session or after needles 
were withdrawn (MOCA 2).  The assessment was done either at the 2nd or the 3rd dialysis 
session of the week depending on patient preference. All patients were in either morning or 
the afternoon shifts of dialysis programme. No medications were administered during dialysis 
with the exception of paracetamol if required. A third cognitive assessment was done a week 
later before dialysis (MOCA 3) in those agreeing to have a further assessment. 
We used the 15-item version of the Geriatric Depression Scale (GDS-15) and the Short 
Confusion Assessment Method (CAM; four items) to rule out depression and delirium 
[23,24]. All three assessments were performed before the start of a haemodialysis session and 
only MOCA was repeated at the end of the same haemodialysis session.  
 
Pre- and post-dialysis body weight, ultrafiltration volume, blood pressure, heart rate and 
oxygen saturation; and symptomatic and asymptomatic intradialytic hypotensive episode 
(blood pressure drop from baseline  of ≥ 20 mmHg) of each participant were obtained over 
the same dialysis session. Demographic details, educational status, comorbidities including 
diabetes status and cardiovascular disease, smoking status, use of psychoactive drugs 
(including antihistamines, sedatives, anti-Parkinsonism and psychotropic drugs), type of 
dialysis fluid used, and laboratory parameters (haemoglobin, white cell count, Kt/V, serum 
urea reduction ratio, sodium, potassium, calcium, phosphate, ferritin, bicarbonate and 
albumin [all taken pre-dialysis]) were extracted from the electronic database. In addition, 
duration of dialysis (in minutes), blood flow rate, dialysate type and dialysate temperature 
were recorded. As per unit protocol, all patients received haemodialysis (none had 
haemodiafiltration) for 240 minutes each using a dialysate temperature of 36 degrees 
centigrade. Also per protocol, all patients were advised to take antihypertensive medications 
at night so as to avoid intra-dialytic hypotension. 
Statistical Analysis: 
Cognitive functions based on the MOCA scores, before and after a single haemodialysis 
session, were compared using a paired t-test. In addition, individual domains of cognitive 
function before and after the single haemodialysis session were compared using a paired t-
test or Wilcoxon signed-rank test for matched-pairs depending on whether scores were 
(approximately) normally distributed. The domains included visuo-spatial, memory, naming, 
attention, language, abstraction, delayed recall and orientation. The relationship between 
cognitive impairment (based on change in MOCA scores before and after haemodialysis, 
represented as MOCA 1 and MOCA 2 respectively) and the putative risk factors was 
examined using linear regression models using two approaches. Firstly, the factors 
considered include age, sex, smoking status, use of psychoactive drugs, comorbidity score 
(Charlson Index), cerebrovascular vascular disease, diabetes, dialysis vintage, haemoglobin, 
total white cell count, serum urea, sodium, potassium, calcium, phosphate, albumin, 
bicarbonate, ferritin, and changes in weight (predialysis – postdialysis), ultrafiltration volume 
and rate, predialysis systolic blood pressure, heart rate, oxygen saturation, and number of 
symptomatic and asymtomatic hypotensive episodes (intradialytic systolic BP drop ≥20 
mmHg), dialysis blood flow rate and dialysate composition. Given that we were exploring a 
large number of variables relative to the sample size, we adopted a systematic approach to 
select only variables that were significant in univariate analyses before fitting the final 
regression models. Secondly, as confounding can both exaggerate or mask potential 
associations, we, a priori, identified nine variables that we considered to be biologically 
important to our hypothesis and incorporated those in a sensitivity analysis using a multiple 
linear regression model irrespective of their significance in univariate modelling. The 
variables included were age, sex, dialysis vintage, Charlson score, cerebrovascular disease, 
use of sedating drugs, change in BP, change in weight. The model was examined for multi-
collinearity. A significance level of 5% was considered throughout and statistical analyses 
were performed using the R statistical package [25]. 
 
Ethics: 
Ethical approval was obtained from the East Midlands National Research Ethics Service 
committee. All participants were provided with patient information leaflets and written 
consent obtained. The study was conducted in accordance with the Declaration of Helsinki 
and institutional good clinical practice framework. 
 
Results: 
Of 176 haemodialysis patients in two centres, 100 met the inclusion criteria; and 82 were able 
to complete both MOCA 1 and MOCA 2 tests. Sixty five patients agreed to have a 3
rd
 
assessment a week later (MOCA 3). Figure 1 shows the flow diagram of study samples. 
Median age was 72 years (53 - 91) and 49 patients (60%) were male. Median dialysis vintage 
was 40 months (range: 3 - 388) and 23 patients (28%) were diabetic. Demographic and 
baseline characteristics are detailed in Table 1. Twenty six patients (31.7%) had 
asymptomatic hypotension (systolic BP drop ≥20 mmHg) over the dialysis session. Sixty two 
patients (76%) had cognitive impairment before/ at the start of HD session (MOCA score 
<24) with 12 (15%) having severe CI (MOCA <17).  
Cognitive function of the cohort declined significantly over the course of a dialysis session 
(MOCA score 20.9±4.9 to 19.1±4.1, p<0.001, Figure 2). In 55 patients (67%) the MOCA 
score declined, median change -3 (range 1 to 9). In 27 patients (33%) the MOCA score 
remained stable or improved slightly, median change +1.5 (range 0-10) (Figure 3).  Seventy-
five patients (91.5%) had cognitive impairment post-haemodialysis (MOCA score <24) with 
20% in severe category (MOCA <17). Most domains of cognitive function were affected 
namely attention, language, abstraction, and delayed recall with a very small improvement in 
orientation.  (Table 2). There was no difference in change in MOCA score (MOCA 1 – 
MOCA2) between those who had MOCA1 before start of HD (median 3.5, range 13 to -15) 
and those who had MOCA 1 in the first half hour of start of HD (median 3, 14 to – 9).  In the 
subgroup of patients (n=65) who had a further assessment within a week, cognitive function 
improved back to their initial pre-dialysis level (MOCA 1 v MOCA 3, 21.2±4.5 v 21.1±4.6, 
p=0.7). 
On univariate linear regression analysis, none of the factors studied correlated with change in 
the MOCA score over HD (MOCA 1 – MOCA 2) except atrial fibrillation (p=0.04) although 
there were only 4 patients out of 82 (0.05%) had atrial fibrillation.  Multiple regression model 
using nine potentially biologically important factors, age and dialysis vintage were 
independently associated with change in the MOCA score (MOCA1 – MOCA2) (Table 3). 
 
Discussion: 
In a cohort of maintenance haemodialysis patients over the age of 50, we have found a 
significant decline in cognitive function over a single dialysis session in majority of patients. 
There were deteriorations in multiple domains of cognition including attention, abstraction, 
delayed recall and language; there was a small but significant improvement in orientation. 
Age and dialysis vintage were independently associated with decline in cognitive function. 
Formatted: Highlight
Consistent with previous observations, 76% of patients had at least mild cognitive 
impairment at the start of haemodialysis session, of which 15% had severe cognitive 
impairment. This is particularly significant given all patients known to have a diagnosis of 
dementia had been excluded from the study. In two thirds of patients cognition declined post-
dialysis with a median decline in MOCA score of 3 (range 1 to 9; 14%). Although this may 
appear to be a small change, it is clinically relevant given the baseline (pre-dialysis) cognitive 
function was significantly below normal. 
Evidence on the effect of a single haemodialysis session on cognition is contradictory. Some 
studies have demonstrated deterioration in cognition over a dialysis session whilst others 
showing improvement mostly a day or so after the dialysis session [4,16-20]. All of these 
studies had small sample sizes (the largest enrolling 57 patients) which might contribute to 
the inconsistent results. The small sample size also limited adjustment for putative risk 
factors [26]. 
 The most recent and best designed of these studies used 28 stable haemodialysis patients and 
a control group from the community with normal kidney function. They assessed cognitive 
function by a battery of neuro-psychological tests before the start of a haemodialysis session 
and 19 hours after the end of haemodialysis demonstrating improvement in some domains of 
cognitive function including memory, psychomotor and executive functions [20]. Although, 
the authors and the accompanying editorial [26] concluded that cognitive function improved 
after a single haemodialysis session, this study actually did not test cognitive function 
immediately after a haemodialysis session.  In our study, cognitive function was tested 
immediately before and after a haemodialysis session in a much larger cohort of patients 
(n=82) demonstrating significant deterioration in cognition. The improvement in cognition on 
further testing in a week pre-dialysis (MOCA 3) further supports the observation that the 
haemodialysis process causes decline in cognitive function, albeit temporary, over 
haemodialysis session in this cohort. The difference in results between studies, i.e. some 
showing improvement in cognitive function post dialysis and others showing decline, appears 
to be related to the timing of the post-dialysis testing; with testing immediately after dialysis 
session showing decline whilst testing hours or a day after showing improvement. We believe 
haemodynamic stress associated with haemodialysis leads to temporary deterioration in 
cognitive function which subsequently recovers after a few hours to show improvement in 
cognitive function which is related to clearance of uraemic toxins during dialysis. However, 
the recurrent transient cerebral insult, reflected in temporary reduction in cognitive function, 
possibly contributes to longer term gradual decline in cognitive function and brain changes as 
discussed below. 
The haemodialysis procedure causes considerable systemic circulatory stress. With loss of 
cerebral arterial autoregulation in these patients, it is possible that the haemodynamic stress is 
transmitted to the cerebral circulation with each haemodialysis session causing recurrent 
cerebral injury [27]. This effect on coronary circulation is now well established with 
intradialytic echocardiographic studies demonstrating myocardial stunning [28,29]. The 
reduction in cardiac contraction further reduces cerebral micro-perfusion [30]. A recent 
randomized controlled study elegantly showed that the use of cool dialysate (1°C below core 
body temperature), known to reduce haemodynamic instability during haemodialysis, 
abrogated the white matter changes in the brain of HD patients, providing indirect evidence 
for the role of recurrent cerebral microcirculatory injury associated with haemodialysis [31]. 
Previous studies have demonstrated correlation between fluctuations in cognitive function 
during haemodialysis and a number clinical and biochemical parameters [18,19,32]. In our 
study, there were no correlation between change in cognition over HD and any of these 
factors on univariate analysis. We also didn’t find correlation between change in cognition 
and intra-dialytic hypotension, dialysis blood flow rate, dialysate flow rate, ultrafiltration 
volume, or history of congestive cardiac failure. However, multiple regression using nine 
potentially biologically important factors in the model showed, age and the length of time the 
patient had been on haemodialysis treatment were independently associated with change in 
cognition over dialysis. Depression, common in haemodialysis patients and known to be 
associated with impaired cognitive function tests [33,34], was also not associated with change 
in cognitive function. Cognitive function starts declining in middle life and progresses with 
age [35]. The association with decline over a dialysis session perhaps suggests increased 
susceptibility to the haemodynamic changes related to haemodialysis with aging. On the 
other hand, the association with dialysis vintage may indicate repetitive ischaemic-
reperfusion injury associated with the haemodialysis process [13] may have a role in 
cognitive decline. 
 
Structural magnetic resonance imaging (MRI) studies of the brain in haemodialysis patients 
showed a preponderance of white matter changes in the form of infarcts, micro-bleeds and 
diffuse changes white matter termed leukoaraiosis [15,36-432]. The cerebral white matter 
structural changes are particularly relevant because of their association with fluctuations in 
cognitive performance [443] as demonstrated in our study. Functional magnetic resonance 
imaging studies (fMRI) showed reduced regional homogeneity in bilateral frontal, parietal 
and temporal regions of the brain in patients with end-stage kidney disease which correlated 
with cognitive function tests. These changes were more prominent in haemodialysis patients 
compared to non-dialysed end-stage kidney disease patients and correlated with cognitive 
impairment, pre-dialysis serum creatinine and duration of haemodialysis [45-465]. Another 
fMRI study of whole brain in haemodialysis patients showed bilateral activation of 
hippocampus suggesting activation of memory-relevant brain areas during dialysis [476]. 
These conclusions suggest that the haemodialysis process may have a role in cognitive 
impairment. 
 
 
Retention of uraemic toxins which are incompletely cleared by haemodialysis may also be 
responsible for chronic cognitive impairment [11,12]. There are more than 200 uraemic 
metabolites most which have unknown effect on cerebral function and clearance by dialysis. 
A recent metabolomic study has identified four uraemic metabolites (4-
hydroxyphenylacetate, phenylacetylglutamine, hippurate, and prolyl-hydroxyproline) which 
were independently associated with impairment of cognitive function [487]. 
 
The results of this study have significant clinical implications. The deterioration in cognitive 
function over a haemodialysis session is associated with impaired capacity to actively process 
and retain information; this in turn is likely to be associated with impaired health literacy and 
ability to perform health related tasks. For example, poor adherence to dietary and medication 
advice given during dialysis could be related to this. As such, reviewing patients and giving 
advice whilst they are undergoing haemodialysis, a common practice in many parts of the 
world, may not be advisable especially towards the latter half of a dialysis session and in 
those showing significant cognitive function decline over haemodialysis. Decline in cognition 
over a haemodialysis session can also affect performance of tasks such as driving and other 
practical skills. It may also affect their capacity to take important decisions or signing 
important documents, like advance directives, during or immediately after haemodialysis. 
One may argue, on the basis of these findings, haemodialysis patients should have cognitive 
function tested periodically, pre and post dialysis, to inform their capacity to undertake tasks, 
such as driving after dialysis. Further research is needed to address this important issue. 
 This study has a number of limitations, the most important of which being the relatively small 
sample size although this study is a bigger cohort than any other study assessing change in 
cognitive function over a dialysis session published to date. Secondly, this study used MOCA 
tool to assess cognitive function. Using a battery of neuro-psychological tests would have 
made the results more robust. The rationale for using MOCA is described in the next 
paragraph. Thirdly, executive function was not examined separately as has been done in some 
previous studies looking at cognitive function in haemodialysis patients at a single time 
point
27
. Fourthly, a MOCA test before the next dialysis showing improvement in cognition 
would support our observations further. However, we were unable to perform this owing to 
logistical reasons. Equally, knowing the MOCA score, before the patient joined the 
haemodialysis programme, would provide a true baseline cognitive function.  Lastly, this 
study did not include a control group for it is difficult to choose an appropriate reference 
group for an observational study involving haemodialysis patients [21]. Healthy individuals 
or those with chronic kidney disease not requiring dialysis cannot be subjected to the dialysis 
procedure for ethical reasons. Peritoneal dialysis patients could be used, but it would be a 
comparison of two different dialysis modalities. Although having haemodialysis patients sit 
for 4 hours without dialysis on the day of their scheduled dialysis may have provided control, 
it is debatable whether this would be ethically justifiable. 
 
The rationale for using the MOCA to assess cognitive function are as follows: 1) The MOCA 
has been validated in haemodialysis patients against a battery of neuropsychological tests 
covering the domains of memory, attention, language, visuospatial and executive functions 
[22].2) It is more sensitive than the Mini Mental State Examination the most commonly used 
screening test [22]. 3) It is of suitable length and takes only 10 minutes to administer. 4) It is 
freely available. 5) There are 3 parallel versions available which help to avoid learning effect 
when cognitive tests are repeated over a short period of time (e.g. before and after a 
haemodialysis session). 6) The MOCA assesses cognitive impairment in 8 domains namely 
visuo-spatial/ executive, memory, naming, delayed recall, orientation, attention, abstraction 
and language functions. 7) It has defined cut scores for clinical cognitive impairment in 
haemodialysis patients [22] and 8) MOCA is adjusted for educational level (+1 for ≤12 year 
of education). All these attributes make MOCA a suitable tool for implementation for routine 
cognitive function assessment in the haemodialysis unit in the future.  
 
The main strength of our work is that it systematically examined the change in cognitive 
function over a haemodialysis session and determined its association with an extensive set of 
covariates related to kidney disease and dialysis that represent important controls via 
exclusion or statistical adjustment, and might potentially be used to determine why 
performance declines after a dialysis session. This has never been done before within a single 
study. Association of change in cognition with educational status was not assessed separately 
as the MOCA is adjusted for education level, and also cognition was compared before and 
after dialysis in the same subjects. 
 
We have demonstrated that there is a significant decline in cognitive function over a 
haemodialysis session involving many domains with age and dialysis vintage being 
independently associated with this decline. The results of this study raise a number of 
questions. What causes this decline in cognitive function over a haemodialysis session? Is it 
related to haemodynamic stress, ischaemic reperfusion injury, in the background of impaired 
cerebral auto-regulation; or is it due to neuro-chemical imbalance associated with 
accumulation uraemic neuro-toxins? Is recurrent ‘cerebral insult’, associated with each 
session of haemodialysis responsible for the more severe and rapidly progressive cognitive 
impairment observed in these patients? And finally, what can we do to help prevent acute and 
the progressive decline in cognition in haemodialysis patients? There is need for further work 
to answer these questions.
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 Legends for figures: 
 
Figure 1: Flow diagram for the study sample 
 
Figure 2: Change in cognitive functions before and after a single haemodialysis session 
and before dialysis one week after 
 
Figure 3: Line charts of changes in cognitive functions over a haemodialysis session in 
individual patients 
 
 
 
 
Table 1: Demographic and other characteristics of the cohort (n=82)  
 
Characteristic Value  
Age (years, median and range,) 73 (53 – 91) 
Sex (male, %) 59 (72%) 
Diabetes (%) 28 (34%) 
Non-smoker (%)  90 
Dialysis vintage (months, median and range) 40.5 (3 – 88) 
Geriatric Depression Score (mean, SD) 4.9 (3.1) 
Charlson Score (mean, SD) 2.6 (1.9) 
Cerebrovascular disease (%) 9 
Use of psychoactive drugs (%) 40 
KT/V (mean and SD) 1.5 (0.3) 
Pre-dialysis BP (mmHg, mean and SD) 142/67 (21/15) 
Post-dialysis BP (mmHg, mean and SD) 130/62 (22/12) 
Pre-dialysis body weight (Kg, median and range) 75.8 (44.9 – 126.5) 
Post-dialysis body weight (Kg, median and range) 72.5 (44.2 – 115.4) 
Change in intra-dialytic systolic BP (mmHg, mean and SD) 11.9 (25.7)   
Blood flow rate (ml/min, mean and SD) 338.8 (56.6)  
Ultrafiltration volume (Litre, median and range) 1.5 (-0.5 – 3.6) 
Haemoglobin (gm/L, mean and SD) 115 (15) 
Serum sodium (mmol/L, mean and SD) 136.3 (2.5) 
Serum potassium (mmol/L, mean and SD) 4.7 (0.8) 
Serum calcium (mmol/L, mean and SD) 2.3 (0.2) 
Serum phosphate (mmol/L, mean and SD) 1.5 (0.4) 
Serum albumin (gm/L, mean and SD) 31.3 (4.2) 
Serum bicarbonate (mmol/L, mean and SD) 23.4 (2.7) 
BP – blood pressure 
Formatted: Highlight
  
Table 2: Summary statistics for cognitive function scores before and after HD session. 
 
Outcome 
Before HD session After HD session  
Mean (SD) 
Median 
(25
th
, 75
th
  percentile) 
Mean (SD) 
Median 
(25
th
, 75
th
  percentile) 
P-value 
MOCA 21 (4.8) 21 (19, 24) 19.1 (4.1) 19 (17, 22) <0.001 
Visuo-spatial 2.8 (1.4) 3 (2, 4) 2.8 (1.4) 3 (2, 4) 0.98 
Naming 2.8 (0.5) 3 (3, 3) 2.8 (0.5) 3 (3, 3) 0.66 
Attention 4.8 (1.4) 5 (4, 6) 4.6 (1.3) 5 (4, 6) 0.05 
Language 1.6 (1) 2 (1, 2) 1 (0.9) 1 (0, 2) <0.001 
Abstraction 1.3 (0.8) 1 (1, 2) 1 (0.8) 1 (0, 2) 0.001 
Delayed recall 2.2 (1.6) 2 (1, 4) 1.2 (1.4) 1 (0, 2) <0.001 
Orientation 5.5 (0.7) 6 (5, 6) 5.7 (0.7) 6 (6, 6) 0.004 
 
 
 Table 3: Multiple regression analyses with regression coefficients (95% CI) for selected biologically 
important risk factors and change in MOCA score. 
 
Variable Beta coefficient (95% CI) P-value 
Age (years) -0.09 (-0.17, -0.01) 0.04* 
Sex (Ref=Female) -0.83 (-2.47, 0.81) 0.32 
Dialysis vintage (months) -0.02 (-0.04, -0.002) 0.03* 
Geriatric depression score -0.18 (-0.47, 0.11) 0.22 
Charlson score -0.13 (-0.6, 0.33) 0.57 
Cerebrovascular disease (Ref=No) 1.13 (-1.69, 3.95) 0.43 
Sedating drugs (Ref=No) 1.14 (-0.47, 2.75) 0.16 
Change in blood pressure (mmHg) -0.02 (-0.05, 0.01) 0.2 
Change in weight (Kg) -0.52 (-1.31, 0.27) 0.19 
 
SBP – systolic blood pressure, GDS – Geriatric depression Scale, *statistically significant 
 
  
 



